Core Insights - Insmed is focused on the impact of its products on patients, particularly highlighting the positive outcomes from its BRINSUPRI product for non-cystic fibrosis bronchiectasis [2] Company Overview - The presentation was led by the CEO, Will Lewis, who emphasized the importance of patient impact in the company's mission [2] - A testimonial from a physician illustrated the significant improvement in a patient's quality of life after using BRINSUPRI, showcasing a reduction in the CAT score from 32 to 6 and a 15% increase in FEV1 [2]

J A N U A R Y 2 0 2 6 © 2026 Bio-Techne®. All rights reserved. | 1 This presentation contains "forward-looking statements" within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, ...

PresentationWe're going to start out with a presentation from the company's CEO, Yvonne Greenstreet, and then we're going to go into some Q&A. [Operator Instructions] But with that, let me pass it over to Yvonne.Good morning, everyone. My name is Jess Fye, biotech analyst at JPMorgan, and we're continuing the 44th Annual JPMorgan Healthcare Conference this morning with Alnylam. Company had a lot of updates yesterday. I'm sure we'll talk about those.Yvonne GreenstreetCEO & Director Thank you, Jessica. Look, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

PresentationGood morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. At the podium, we have the CEO of PTC Therapeutics, Matt Klein. I'll now pass the mic to Matt for a short presentation, followed by a live audience Q&A.Matthew KleinCEO & Director Thank you, Brian, and thank you, everyone, for joining us this morning. Last year, I stood on this stage and talked about how 2025 was going ...

PresentationKicking off the conference, we have BridgeBio. And then presenting on behalf of the company, we have CEO, Neil Kumar. Neil?All right. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, Joyce Zhou and Rati Pinge.Neil KumarCo-Founder, CEO & Director Well, thanks, everyone, for taking the time this morning. I'd like to thank Mike, Ben and the entire JPMorgan t ...

Presentation Richard VosserJPMorgan Chase & Co, Research Division Welcome to the first day of the 44th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce argenx CEO, Timothy Van Hauwermeiren. Just a few housekeeping rules. We will take questions from the room after Tim's presentation and/or you can submit those into the portal. So with that, Tim, welcome to the conference. Tim Van HauwermeirenCo-Founder, CEO & Executive Director Th ...

PTC Therapeutics (NasdaqGS:PTCT) FY Conference January 12, 2026 12:00 PM ET Company ParticipantsRoss Taylor - CFOOguzhan Atay - Co-founder and CEOMatthew B. Klein - CEOConference Call ParticipantsBrian Cheng - Senior Biotech AnalystCasey Woodring - AnalystBrian ChengGood morning, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. At the podium, we have the CEO of PTC Therapeutics, Matt Klein ...

CRISPR Therapeutics (NasdaqGM:CRSP) FY Conference January 12, 2026 11:15 AM ET Company ParticipantsDiana Ramos - SurgeonCharles Bruce - Medical ExpertSamarth Kulkarni - CEOConference Call ParticipantsNone - AnalystBrian Cheng - Senior Biotech AnalystBrian Chengto another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Chang. I'm one of the senior biotech analysts here at the firm. On stage, we have Sam from CRISPR Therapeutics. I'll now pass the mic to their CEO, Sam, for a short presentati ...

Lumexa Imaging (NasdaqGS:LMRI) FY Conference January 12, 2026 10:30 AM ET Company ParticipantsCaitlin Zulla - CEOTony Martin - CFOChristian Behrenbruch - CEOJason Coloma - CEOConference Call ParticipantsNone - AnalystAnupam Rama - Senior Biotech AnalystBen Rossi - Healthcare Facilities AnalystChris Cooper - Australian Healthcare AnalystBen RossiThank you all for joining us here in person. And for those joining us via webcast, my name is Ben Rossi, and I'm the Healthcare Facilities Analyst here at JPMorgan. ...